Kalos Therapeutics
Kalos Therapeutics is a biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer.
Kalos has been covered by ABC News on Good Morning America, and profiled in Business Week. The company aggressively targets diseases caused by an abnormally high growth rate of cells (hyper proliferation), and is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.
KT-220, the current lead [...] candidate, demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.
Board Members
George Colberg - Chairman & CEO
James Merritt, M.D. - President and Chief Medical Officer
Gregory F. Witchel, MBA - Executive Vice President
Daniel Von Hoff, MD, FACP - Chairman, Scientific Advisory Board
David L. Vesely, MD, PhD - Scientific Advisory Board
Marc B. Garnick, MD - Scientific Advisory Board
Patrice P Rioux, MD, PhD - Scientific Advisory Board
Affiliated Organizations
Covidien, Translational Genomics Research Institute, TGen [...] Development, Gentech Pharmaceutical, Arizona College of Ophthalmology, MonoSol RX, Q Chip
References
External Links